Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment

Blood

Volumn 116, Issue 2, 2010, Pages 270-279

  Mei, Baisong ^a   Pan, Clark ^a   Jiang, Haiyan ^a   Tjandra, Hendri ^a   Strauss, Jonathan ^a   Chen, Yaoqi ^a   Liu, Tongyao ^a   Zhang, Xin ^a   Severs, Joanne ^a   Newgren, Jim ^a   Chen, Jianmin ^a   Gu, Jian Ming ^a   Subramanyam, Babu ^a   Fournel, Michael A ^a   Pierce, Glenn F ^a   Murphy, John E ^a  

^a BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; CYSTEINE; MACROGOL; VON WILLEBRAND FACTOR; COAGULATING AGENT; MACROGOL DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; BLOOD CLOTTING; CONJUGATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; EXPERIMENTAL RABBIT; HEMOPHILIA A; KNOCKOUT MOUSE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN EXPRESSION; ANIMAL; CHEMISTRY; DELAYED RELEASE FORMULATION; HALF LIFE TIME; MASS SPECTROMETRY; MOUSE MUTANT; POLYACRYLAMIDE GEL ELECTROPHORESIS; RABBIT; SITE DIRECTED MUTAGENESIS; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; COAGULANTS; DELAYED-ACTION PREPARATIONS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FACTOR VIII; HALF-LIFE; HEMOPHILIA A; MICE; MICE, KNOCKOUT; MUTAGENESIS, SITE-DIRECTED; POLYETHYLENE GLYCOLS; RABBITS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 77955492929     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-11-254755     Document Type: Article

References (42)

1. Vehar GA, Keyt B, Eaton D, et al. Structure of human factor VIII. Nature. 1984;312(5992):337-342.
2. Lillicrap D. Extending half-life in coagulation factors: where do we stand? Thromb Res. 2008;122(suppl 4):S2-S8.
3. Björkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet. 2001;40(11):815-832. (Pubitemid 33095998)
4. Björkman S, Folkesson A, Jönsson S. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eur J Clin Pharmacol. 2009;65(10):989-998.
5. Lenting PJ, Neels JG, van den Berg BMM, et al. The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein. J Biol Chem. 1999;274(34):23734-23739.
6. Saenko EL, Yakhyaev AV, Mikhailenko I, Strickland DK, Sarafanov AG. Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism. J Biol Chem. 1999;274(53):37685-37692.
7. Bovenschen N, Boertjes RC, van Stempvoort G, et al. Low density lipoprotein receptor-related protein and factor IXa share structural requirements for binding to the A3 domain of coagulation factor VIII. J Biol Chem. 2003;278(11):9370-9377.
8. Bovenschen N, Mertens K, Hu L, Havekes LM, van Vlijmen BJM. LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII in vivo. Blood. 2005;106(3):906-912.
9. Sarafanov AG, Ananyeva NM, Shima M, Saenko EL. Cell surface heparan sulfate proteoglycans participate in factor VIII catabolism mediated by low density lipoprotein receptor-related protein. J Biol Chem. 2001;276(15):11970- 11979. (Pubitemid 37385357)
10. Bovenschen N, Rijken DC, Havekes LM, Vlijmen BJM, Mertens K. The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor. J Thromb Haemost. 2005;3(6):1257-1265. (Pubitemid 41725251)
11. Tuddenham EGD, Lane RS, Rotblat F, et al. Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease. Br J Haematol. 1982;52(2):259-267. (Pubitemid 12033978)
12. Schwarz HP, Schlokat U, Mitterer A, et al. Recombinant von Willebrand factor-insight into structure and function through infusion studies in animals with severe von Willebrand disease. Semin Thromb Hemost. 2002;28(02):215-226.
13. Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor: studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest. 1977;60(2):390-404.
14. Veronese FM, Mero A. The impact of PEGylation on biological therapies. Biodrugs. 2008;22(5):315-329.
15. Bailon P, Won C-Y. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv. 2009;6(1):1-16.
16. Fishburn CS. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci. 2008;97(10):4167-4183.
17. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev. 2002;54(4):459-476.
18. Röstin J, Smeds A-L, Akerblom E. B-domain deleted recombinant coagulation factor VIII modified with monomethoxy polyethylene glycol. Bioconjug Chem. 2000;11(3):387-396. (Pubitemid 30324905)
19. McMullen BA, Fujikawa K, Davie EW, Hedner U, Ezban M. Locations of disulfide bonds and free cysteines in the heavy and light chains of recombinant human factor VIII (antihemophilic factor A). Protein Sci. 1995;4(4):740-746.
20. Stoilova-McPhie S, Villoutreix BO, Mertens K, Kemball-Cook G, Holzenburg A. 3-Dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography. Blood. 2002;99(4):1215-1223.
21. Ngo JCK, Huang M, Roth DA, Furie BC, Furie B. Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex. Structure. 2008;16(4):597-606.
22. Shen BW, Spiegel PC, Chang C-H, et al. The tertiary structure and domain organization of coagulation factor VIII. Blood. 2008;111(3):1240-1247.
23. Lind P, Larsson K, Spira J, et al. Novel forms of B-domain-deleted recombinant factor VIII molecules. Eur J Biochem. 1995;232(1):19-27.
24. Cho M-S, Yee H, Brown C, Mei B, Mirenda CA, Chan S. Versatile expression system for rapid and stable production of recombinant proteins. Biotechnol Prog. 2003;19(1):229-232.
25. Cho M-S, Yee H, Chan S. Establishment of a human somatic hybrid cell line for recombinant protein production. J Biomed Sci. 2002;9631-638.
26. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet. 1995;10(1):119-121.
27. Denis C, Methia N, Frenette PS, et al. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci U S A. 1998;95(16):9524-9529. (Pubitemid 28506264)
28. Pan J, Liu T, Kim J-Y, et al. Enhanced efficacy of recombinant FVIII in non-covalent complex with PEGylated liposome in hemophilia A mice. Blood. 2009;114(13):2802-2811.
29. Terraube V, O'Donnell JS, Jenkins PV. Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance. Haemophilia. 2009;20091-11.
30. Ganz PR, Atkins JS, Palmer DS, Dudani AK, Hashemi S, Luison F. Definition of the affinity of binding between human von Willebrand factor and coagulation factor VIII. Biochem Biophys Res Commun. 1991;180(1):231-237.
31. Vlot AJ, Koppelman SJ, van den Berg MH, Bouma BN, Sixma JJ. The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor. Blood. 1995;85(11):3150-3157.
32. Sandberg H, Almstedt A, Brandt J, et al. Structural and functional characteristics of the B-domain deleted recombinant factor VIII protein, r-VIII SQ. Thromb Haemost. 2001;85(1):93-100. (Pubitemid 32050949)
33. Ananyeva NM, Lacroix-Desmazes S, Hauser CAE, et al. Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives. Blood Coagul Fibrinolysis. 2004;15(2):109-124. (Pubitemid 38392362)
34. Shima M. Characterization of factor VIII inhibitors. Int J Hematol. 2006;83(2):109-118.
35. Healey JF, Lubin IM, Nakai H, et al. Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII. J Biol Chem. 1995;270(24):14505-14509.
36. Lollar P, Parker ET, Curtis JE, et al. Inhibition of human factor VIIIa by anti-A2 subunit antibodies. J Clin Invest. 1994;93(6):2497-2504. (Pubitemid 24177164)
37. Ansong C, Miles SM, Fay PJ. Epitope mapping factor VIII A2 domain by affinity-directed mass spectrometry: residues 497-510 and 584-593 comprise a discontinuous epitope for the monoclonal antibody R8B12. J Thromb Haemost. 2006;4(4):842-847.
38. Ahmad SS, Walsh PN. Role of the C2 domain of factor VIIIa in the assembly of factor-X activating complex on the platelet membrane. Biochemistry. 2005;44(42):13858-13865.
39. Gaberc-Porekar V, Zore I, Podobnik B, Menart V. Obstacles and pitfalls in the PEGylation of therapeutic proteins. Curr Opin Drug Discov Devel. 2008;11(2):242-250. (Pubitemid 351281064)
40. Pan CQ, Buxton JM, Yung SL, et al. Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist. J Biol Chem. 2006;281(18):12506-12515.
41. Junutula JR, Raab H, Clark S, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotech. 2008;26(8):925-932.
42. Lenting PJ, van Schooten CJM, Denis CV. Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost. 2007;5(7):1353-1360. (Pubitemid 46965358)